Drug Trial Radar · NCT02759315
Efficacy and Safety of Uprifosbuvir (MK-3682) With Ruzasvir (MK-8408) in Adults With Chronic Hepatitis C Genotype 1, 2, 3, 4, 5 or 6 Infection (MK-3682-035)
Last checked: Nov 20, 2026Latest source record: Jun 26, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
160
Actual
Start
May 3, 2016
Primary completion
Jul 27, 2017
Study completion Nov 16, 2017
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- May 3, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is an open-label, multi-center trial to evaluate the novel 2-drug regimen of uprifosbuvir (MK-3682) 450 mg and ruzasvir (MK-8408) 60 mg in participants with chronic hepatitis C virus (HCV) genotype (GT)1, GT2, GT3, GT4, GT5, or GT6 infection. The impact of the study treatment regimen on the percentage of participants with undetectable HCV ribonucleic acid \[RNA\] 12 weeks after completing study treatment (SVR12) will be evaluated.
Conditions
- Hepatitis C, Chronic
Interventions
Uprifosbuvir 450 mgDrug
450 mg administered as 3 x 150 mg oral tablets
Ruzasvir 60 mgDrug
60 mg administered as 6 x 10 mg oral capsules
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving Sustained Virologic Response 12 Weeks After Completing Study Therapy (SVR12)Time frame: Week 24 (12 weeks after completing study therapy)
- Percentage of Participants With ≥1 Adverse Events (AEs)Time frame: Up to Week 14 (up to 2 weeks after completing study therapy)
- Percentage of Participants Withdrawing From Study Therapy Due to an AETime frame: Up to Week 12
- Percentage of Participants With ≥1 Events of Clinical Interest (ECIs)Time frame: Up to Week 14 (up to 2 weeks after completing study therapy)
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.